Safety and efficacy of dendritic cell vaccine for COVID-19 prevention after 1-Year follow-up: phase I and II clinical trial final result

INTRODUCTION: Interim analysis of phase I and phase II clinical trials of personalized vaccines made from autologous monocyte-derived dendritic cells (DCs) incubated with S-protein of SARS-CoV-2 show that this vaccine is safe and well tolerated. Our previous report also indicates that this vaccine c...

Descripción completa

Detalles Bibliográficos
Autores principales: Jonny, Jonny, Putranto, Terawan Agus, Yana, Martina Lily, Sitepu, Enda Cindylosa, Irfon, Raoulian, Ramadhani, Bunga Pinandhita, Sofro, Muchlis Achsan Udji, Nency, Yetty Movieta, Lestari, Endang Sri, Triwardhani, Ria, Mujahidah, Sari, Retty Karisma, Soetojo, Nur Alaydrus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315914/
https://www.ncbi.nlm.nih.gov/pubmed/37404828
http://dx.doi.org/10.3389/fimmu.2023.1122389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315914/
https://www.ncbi.nlm.nih.gov/pubmed/37404828
http://dx.doi.org/10.3389/fimmu.2023.1122389

Ejemplares similares